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Intermittent versus continuous administration of 1,25-dihyroxyvitamin
D3 in experimental renal hyperparathyroidism. Conflicting results have
been reported regarding the efficacy of intermittent versus continuous
administration of I ,25(OH)2D3 in renal secondary hyperparathyroidism.
To address this issue we examined sham-operated control rats and
hyperparathyroid rats with subtotal (5/6) nephrectomy (Nx). The Nx
animals (20 to 22 animals per group) were subjected to three treatment
protocols: (i) solvent treatment (Nx-solvent); (ii) two i.p. injections of
35 pmol I ,25(OH)2D3 on days 0 and 4 (Nx-bolus); and (iii) continuous
infusion of 70 pmol 1 ,25(OH)2D3 over six days via osmotic minipump
(Nx-infusion). All measurements were performed six days after start of
treatment. As compared to sham-operated controls, the pre-pro-PTH/
f3-actin mRNA ratio was 2.04-fold higher in Nx-solvent. Both modes of
administration of 1 ,25(OH)2D3 resulted in inhibition of PTH mRNA
concentrations relative to Nx-solvent. The pre-pro-VFH/J3-actin mRNA
ratio was, however, significantly lower (P < 0.05) in Nx-bolus than in
Nx-infusion (Nx-bolus 1.26 higher than sham-operated controls; Nx-
infusion 1.65 higher than sham-operated controls). Aminoterminal PTH
(N-PTH) serum concentrations were higher in Nx-solvent (52 4
pg/mI) than in sham-operated controls (32 3 pg/mI, P < 0.01). N-PTH
concentrations in Nx-bolus (38 4 pg/mI) were significantly lower than
in Nx-solvent (P < 0.01) and in Nx-infusion (46 4 pg/mI, P < 0.05).
Parathyroid gland weight (sg/g body wt) was higher in Nx-solvent (1.30
0.08 pg/mI) than in sham-operated controls (0.79 0.04 pg/mI, P <
0.02). Again, parathyroid weight was lower in Nx-bolus (0.99 0.014
pg/mi, P <0.05 vs. Nx-solvent) than in Nx-infusion (1.16 0.06pg/mI).
Differential effects of bolus versus infusion treatment were not ex-
plained by changes in serum calcium or phosphate. Analysis of the
1 ,25(OH)2D3 concentration time-profile showed higher peak concentra-
tions in bolus-treated animals (170 to 200 pg/mI after 8 hr) than in
infusion-treated animals (125 to 130 pg/mI after 48 hr). The time-
averaged mean increase in 1 ,25(OH)2D3 serum concentrations was,
however, higher in infusion-treated animals (42.3 pg/mI/24 hr) than in
bolus-treated animals (26.0 pg/ml124 hr). We conclude that the stimu-
lation of parathyroid gland function in experimental uremia is more
effectively suppressed when the same total dose of I ,25(OH)2D3 is given
by intermittent bolus administration than by continuous infusion. Our
results are compatible with the notion that the I ,25(OH)2D3 concentra-
tion time-proffie, that is, the l,25(OH)2D3 peak concentration, is an
important determinant of the response of parathyroid glands to
1 ,25(OH)2D3.
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The use of la,25-dihydroxyvitamin D3 [l,25(OH)2D3] in the
treatment of secondary hyperparathyroidism of chronic renal
failure is well-established. The optimal mode of administration
of l,25(OH)2D3 has, however, not been clarified. Whereas
initially, daily doses of 1 ,25(OH)2D3 were given per os [1—3],
Slatopolsky et al [4] proposed an intermittent mode of admin-
istration by intravenous injection. The efficacy of intermittent
administration of bioactive vitamin D metabolites has been
confirmed by subsequent investigators [5—10], but the mecha-
nism explaining the unique efficacy of intermittent intravenous
therapy has not been completely clarified. One possible expla-
nation is that bioavailabiity of 1 ,25(OH)2D3 after intravenous
administration is higher, since initial hepatic metabolism (as
occurs with oral administration) is circumvented. This point has
been clearly demonstrated by Salusky et al [11]. It is possible,
however, that not only the route, but also the temporal pattern
of administration (bolus vs. continuous) may be important,
since intermittent oral 1 ,25(OH)2D3 therapy is also effective
[12—151. A controlled comparison of either mode of therapy is
not yet available.
To further address the issue whether the temporal pattern of
I ,25(OH)2D3 administration influences the effect of the hor-
mone on the parathyroids, experiments were carried out with
subtotally nephrectomized rats. The animals were given the
same total dose of 1 ,25(OH)2D3 either continuously via osmotic
minipump or intermittently by i.p. injections. The results dem-
onstrate greater suppression of parathyroid function by bolus
administration.
Methods
Animals
Male Sprague-Dawley rats, weighing between 180 and 220 g
(Ivanovas Co., Kisslegg, Germany), were either sham-operated
(decapsulation of kidney) or subjected to two-step subtotal
nephrectomy (Nx) under Ketamine (Parke-Davis Inc., Berlin,
Germany) anesthesia. Following surgery, animals were kept in
an environment with controlled light (12 hr on/l2 hr off cycles),
constant temperature (22°C) and humidity (70%). After ne-
phrectomy, animals were maintained on a low calcium diet with
0.079% (wt/wt) calcium, 0.65% (wt/wt) inorganic phosphate,
and 400 U/kg vitamin D3 (Fa. Altromin, Lage, Germany). The
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animals had free access to normal drinking water. Sham-
operated control animals received a diet containing 0.95%
(wtlwt) calcium and 0.75% (wt/wt) inorganic phosphate (Al-
tromin). At the time of sacrifice, parathyroid glands were
excised by microsurgical techniques. Absence of thyroid tissue
was confirmed histologically in four to five randomly sampled
glands per experiment.
Experimental procedures
A six-day treatment period with 1 ,25(OH)2D3 was begun 21
days after nephrectomy. Two days prior to treatment, serum
creatinine was measured in Nx animals, and experimental
groups (N = 20 to 22) with matching elevations of serum
creatinine concentrations were established: (i) solvent-treated
Nx animals (Nx-solvent). (ii) Animals were treated with two i.p.
injections of 35 pmol 1 ,25(OH)2D3. The first injection was given
on the first day of the treatment period (at 9 a.m.), and the
second injection on the fourth day (9 a.m.) of the six-day
treatment period (Nx-bolus). (iii) Animals received an infusion
of 70 pmol 1 ,25(OH)2D3 over six days via osmotic minipump
(Nx-infusion). Thus, both bolus-treated and infusion-treated
animals received the same total dose of 1 ,25(OH)2D3 (70 pmol).
Experiments were terminated six days after the beginning of
treatment with I ,25(OH)2D3. Unless indicated otherwise, mea-
surements were made at the end of the six-day treatment
period. The experimental protocol was chosen since pilot
experiments had shown that this dose of I ,25(OH)2D3 caused
detectable inhibition of VFH-synthesis within the study period
of six days without causing hypercalcemia. The 1 ,25(OH)2D3
(gift of Dr. Calcanis, Hoffmann-LaRoche, Inc., Grenzach,
Germany) was stored at —20°C in absolute ethanol. For exper-
iments, the 1 ,25(OH)2D3 was dissolved in propylene glycol.
Osmotic minipumps (Alzet 2001, AIza Research Inc., Palo Alto,
California, USA) were implanted subcutaneously in the neck of
the animals under ether anesthesia. After explantation, delivery
of 1 ,25(OH)2D3 in vivo was verified by quantitating the volume
remaining in the minipumps. Adequate delivery of 1 ,25(OH)2D3
from minipumps was further checked in a pilot experiment (N =
3) by measuring the appearance of tritiated 1 ,25(OH)2D3 in
blood, intestinal mucosa and remnant kidney using high perfor-
mance liquid chromatography [16].
In further experiments, 1 ,25(OH)2D3 serum concentrations
were monitored in Nx animals after i.p. injection of
1 ,25(OH)2D3 or during continuous infusion of 1 ,25(OH)2D3
using the experimental protocol described above. Blood (N =S
per time-point) was taken at 4, 8, 12, 24, 48 and 72 hours after
i.p. injection of 35 pmol of 1 ,25(OH)2D3. Additional measure-
ments of 1 ,25(OH)2D3 serum concentrations were carried out at
4, 8, 24, 48 and 72 hours after a second injection of 35 pmol
1 ,25(OH)2D3 which was given 72 hours after the first injection.
The concentration time profile of 1 ,25(OH)2D3 in animals
with osmotic minipumps was evaluated by measuring
1 ,25(OH)2D3 concentrations 24, 48, 72, 96, and 144 hours after
implantation of osmotic minipumps (N = 5 per time-point).
Preparation of RNA
Parathyroid glands were flash frozen in liquid nitrogen and
stored at —80°C. Approximately 35 parathyroid glands were
harvested from the animals of one experimental group. Fifteen
to 20 parathyroid glands were pooled for the extraction of one
cellular RNA sample. The tissue pools were collected to obtain
sufficient RNA for quantitation by UV spectrophotometry.
Tissue samples were homogenized in 4 M guanidinium isothio-
cyanate and centrifuged on a cesium trifluoroacetate cushion at
125,000 g for 24 hours at 15°C [17]. RNA quantity and purity
were evaluated by measuring absorbances at 260 nm and 280
nm. One pool of glands typically yielded approximately 7 g
RNA in sham-operated controls to 12 z.g RNA in Nx-solvent.
Northern blot analysis
Cellular RNA (5 pg/sample) was fractionated under denatur-
ing conditions on a 1.2% formaldehyde-agarose gel, transferred
to a nylon filter (Hybond-N membrane, Amersham, Braun-
schweig, Germany) in 20 X SSC (1 X =0.15 M NaCI and 0.015
M trisodium citrate) and immobilized on filters by baking for
two hours at 80°C [18].
Hybridization with 32P-labeled probes
All probes were labeled with a32P-dCTP (3000 mCi/mmol
Amersham) by the random priming method of Feinberg and
Vogelstein [19]. The specific activity of the probes was approx-
imately 2 x 108 cpm/g DNA.
The filters were prehybridized for four hours at 42°C in a
solution containing 50% formamide, 5 x SSC, 5 x Denhardt's
solution, 0.1% sodium dodecyl sulfate (SDS), and 100 jsg/ml
sonicated herring sperm DNA. Hybridization was carried out
for 12 hours at 42°C in a solution containing 50% formamide, 5
x SSC, 0.1 g/ml dextran sulfate, 0.2% SDS, and 100 pg/mi
fragmented herring sperm DNA, using 1 x 106 cpmlml 32P-
labeled DNA/filter. After hybridization, filters were washed
twice for 15 minutes in 2 x SSC, 0.1% SDS at room tempera-
ture, once for 15 mm in 1 x SSC, 0.1% SDS at 65°C, and once
for 15 minutes in 0.7 x SSC, 0.1% SDS at 65°C. The blots were
air-dried and exposed to Kodac XAR-5 film at —80°C in the
presence of intensifying screens. After hybridization with the
PTH probe, filters were washed in 1% SDS, 0.1 x SSC for one
hour at 70°C and then rehybridized with the /3-actin probe. The
intensities of autoradiographs were quantitated by densitometry
using a LKB Ultrascan XL densitometer (LKB, Bromma,
Sweden). In repeat scans, coefficient of variation was less than
5%.
Probes
A genomic DNA fragment corresponding to exons 2 and 3 of
the rat pre-pro-PTH gene cloned in pGEM4 (bp 1691—2071 [20])
was a gift of Dr. H. Kronenberg (Harvard University, Boston,
Massachusetts USA). A human full-length /3-actin cDNA was
from Clontech (Palo Alto, California, USA).
Other measurements
Serum creatinine, inorganic phosphate, and albumin were
measured by autoanalyzer technique. Serum calcium was mea-
sured by flame absorption spectrophotometry. Aminoterminal
PTH (N-PTH) serum concentrations were determined using a
commercially available assay kit according to the protocol of
the manufacturer (INS-PTH kit, Nichols Institute, San Juan
Capistrano, California, USA). The assay has been validated for
measurement of rat samples [21, 22].
Serum 25(OH)D3 concentrations were determined by com-
petitive protein binding assay as described previously [23]
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Table 1. Effects of various treatments on serum concentrations of calcium-regulating hormones, mineral ions, creatinine, albumin, and on
food intake and growth
Sham-op. controls
(N = 20—25)
Nx-solvent
(N = 35—40)
Nx-bolus
(N = 35—40)
Nx-infusion
(N = 35—40)
N-PTH pg/mi 32 52 4 38 4b,d 46 4
25(OH)D3 ng/ml 69 9 77 19 85 30 82 21
1,25(OH)2D3 pg/mi 76 21 54 13 51 7 112 12b
Creatinine mgldl 0.57 0.04 1.06 0.12° 1.11 0.10° 1.08 0.12°
Calcium mmoi/iiter 2.47 0.08 2.46 0.06 2.70 0.10" 2.64 O.O8
Phosphate mmol/iiter 2.28 O.2l' 2.02 0.13 2.18 0.17a 2.21 0.21"
Albumin g/dl 33.0 1.5 30.3 1.3° 30.4 1.3° 29.9 1.4°
Body weight g 239 6 224 8 224 5 226 10
Food intake g/day 14.2 1.3 13.7 1.2 13.5 0.4 13.4 0.6
Data (means SE) of measurements after 6 days of treatment. Combined results of four independent experiments. Analysis of data by ANOVA.
Abbreviation is N-PTH, aminoterminal PTH.
a P < 0.05 vs. Nx-solvent
b P < 0.01 vs. Nx-solvent
C P < 0.01 vs. sham-operated controlsd P < 0.05 vs. Nx-infusion
P < 0.01 vs. Nx-infusion
utilizing the plasma vitamin D binding protein. Measurement of
1 ,25(OH)2D3 serum concentrations was done by radioimmuno-
assay [24]. Prior to assay, vitamin D metabolites were extracted
from serum by ExtrelutR columns; 1 ,25(OH)2D3 was separated
from other vitamin D metabolites by high performance liquid
chromatography.
Protein was measured according to Lowry et a! [25]. [3H]-
Thymidine incorporation ex vivo into parathyroid glands was
measured as described previously [26]. For measurements of
DNA synthesis, 13 to 19 parathyroid glands per group were
pooled in 1 ml of minimum essential medium (MEM, Gibco) at
4°C. The glands were incubated with 5Ci [methyl-3H]-thymi-
dine (specific activity 5 Ci/mmol, Amersham) in I ml MEM for
one hour at 37°C in a water bath.
After incubation, the parathyroid glands were homogenized
in a glass homogenizer, ultrasonicated and solubilized as de-
scribed previously [26]. After centrifugation at 10,000 g for 10
minutes at 4°C, the DNA in the pellet was precipitated with
tnchloroacetic acid and resuspended in 1 ml of 1 M KOH.
Aliquots of this solution were utilized for determination of
[3H]-thymidine incorporation by liquid scintillation counting
and for protein measurements.
Statistics
Comparisons of the means were made by ANOVA followed
by the Duncan test. Results are expressed as means SE.
Results
Four weeks after 5/6 nephrectomy, serum creatinine was
elevated to 1.06 0.12 mg/dl in Nx-solvent as compared to 0.57
0.04 mg/dI in sham-operated control animals (Table 1). Serum
concentrations of total calcium and 25(OH)D3 did not differ
between sham-operated controls and Nx-solvent (Table 1).
Serum phosphate and albumin concentrations were lower in
Nx-solvent than in sham-operated control animals.
Effects of intermittent versus continuous administration of
1,25(OH)2D3
The data in Table 1 show that serum creatinine, vitamin D
status [25(OH)D3 serum concentrations], serum albumin con-
centrations, body weight and food intake of uremic animals
were comparable between Nx-solvent and the two treatment
groups (Nx-bolus and Nx-infusion).
Pre-pro-PTH/f3-actin mRNA ratio in parathyroid glands.
Pre-pro-PTH mRNA and /3-actin mRNA concentrations in
pooled parathyroid tissue from the experimental groups were
measured in several replicate experiments. A summary of RNA
data is given in Figure 1A. As compared to sham-operated
control animals, the FFH//3-actin mRNA ratio was elevated
approximately twofold in Nx-solvent. When the pre-pro-PTHI
/3-actin mRNA ratio in sham-operated controls was set at 1.00
the pre-pro-PTH//3-actin mRNA ratio was, on average, 2.04 in
Nx-solvent. Taken together, mean suppression of PTH mRNA
by 1 ,25(OH)2D3 was significantly greater (P < 0.05) after two
i.p. injections of 35 pmol 1 ,25(OH)2D3 than after the continuous
infusion of the same total dose of 1 ,25(OH)2D3. The pre-pro-
PTH//3-actin mRNA ratio was 1.26 in Nx-bolus and 1.65 in
Nx-infusion.
The Northern blot analysis of RNA from a single experiment
is shown in Figure lB. In this experiment, the pre-pro-PTH/f3-
actin mRNA ratio in Nx-solvent was elevated by 2.36 as
compared to sham-operated controls. The PTH/f3-actin mRNA
ratio was more reduced in Nx-bolus (by 44% vs. Nx-solvent)
than in Nx-infusion (by 35% vs. Nx-solvent).
Aminoterminal PTH (N-PTH) serum concentrations. As
compared to sham-operated control animals, the mean N-PTH
serum concentration was approximately 60% higher (52 pg/mI
vs. 32 pg/mI) in Nx-solvent (Table 1). Nx-bolus had significantly
lower N-PTH serum concentrations than Nx-solvent and Nx-
infusion, respectively. Nx-infusion also had significantly lower
N-PTH concentrations than Nx-solvent (Table 1).
Parathyroid gland weight. Nx-solvent had significantly
higher parathyroid weight (1.30 0.08 &g/g body wt) than
sham-operated control animals (0.79 0.04 p.g/g, Fig. 2).
Nx-bolus animals had significantly reduced parathyroid weight
(0.99 0.14 zg/g) as compared to Nx-solvent. Parathyroid
weight of Nx-infusion animals was slightly but not significantly
reduced versus Nx-solvent. When the mean parathyroid gland
weight in sham-operated controls was set at 1.00, parathyroid
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Fig. 1. Effect of bolus versus continuous 1,25(OH)2D3 administration
on pre-pro-PTH mRNA concentrations. A. Summary of pre-pro-PTH/
13-actin mRNA ratios after quantitation by laser densitometry (mean
SE). Data are presented as percent of OD readings in sham-operated
control animals (intact). The results from Nx-solvent, Nx-bolus and
Nx-infusion are from six pools of parathyroid glands (15 to 20 glands per
sample) from three independent experiments. Results from sham-
.2 operated control animals are from three pools of parathyroid glands
from two independent experiments. Symbols are: (*) P < 0.01 versus
< intact; (0) P < 0.05 versus Nx-infusion; (•) P < 0.05 versus Nx-Z . solvent. (Nx, Nx-Solvent). B. A Northern blot analysis of total RNA (5
E pg/lane) from parathyroid glands (15 to 20 pooled glands/point) is
shown. The blot was sequentially hybridized with a 32P-labeled genomic
PTH probe (upper panel) and a 32P-labeled 13-actin cDNA (lower panel).
.
Lane 1: Nx-solvent, vehicle-treated uremic animals. Lane 2: Nx-bolus,
two i.p. injections of 35 pmol 1 ,25(OH)2D3 at days 0 and 4. Lane 3:
Nx-infusion, continuous infusion of 70 pmol I ,25(OH)2D3 by osmotic
minipumps over 6 days. Lane 4: sham-operated control animals. The
PTH//3-actin ratios in this blot were as follows: sham-operated controls
set at 1.00; Nx-solvent 2.36; Nx-bolus 1.32; Nx-infusion 1.53.
gland weights were 1.65 in Nx-solvent, 1.25 in Nx-bolus, and
1.47 in Nx-infusion.
To determine the increase in pre-pro-PTH mRNA per animal,
one has to consider both the increase in pre-pro-PTH//3-actin
mRNA ratio and the increase in parathyroid weight. Assuming
that actin mRNA per cell is invariant, the product of RNA ratio
and relative parathyroid weight will be a function of pre-pro-
PTH mRNA per animal. If this product in sham-operated
controls was set at 1.00, the value in Nx-solvent was 3.37, in
Nx-bolus 1.58, and in Nx-infusion 2.43.
PTH DNA synthesis cx vivo in pooled parathyroid tissue. Because
of limited availibility of material, DNA synthesis in parathyroid
glands was assessed by measuring [3H]-thymidine incorporation
ex vivo into pooled glands in one single study. [3H]-thymidine
incorporation rose more than twofold in Nx-solvent as com-
pared to sham-operated controls (from 1220 dpmlmg protein to
2630 dpmlmg). Both modes of 1 ,25(OH)2D3 administration
reduced the incorporation of [3H]-thymidine slightly below the
level which was found in sham-operated controls.
Serum concentrations of calcium and phosphate. As com-
pared to Nx-solvent, both treatment modes caused a compara-
ble rise in serum calcium concentrations (Table 1). Serum
phosphate also increased after both modes of 1 ,25(OH)2D3
treatment in a comparable fashion (Table 1).
1,25(OH)2D3 concentration time-profile after bolus
administration and during continuous infusion
As shown in Table 1, infusion of 70 pmol 1 ,25(OH)2D3 over a
six day period resulted in a more than twofold elevation of
1 ,25(OH)2D3 serum concentrations (vs. Nx-solvent) at the end
of the experiment. In contrast, 1 ,25(OH)2D3 serum concentra-
Actin tions in the bolus group three days after the second injection
were comparable to concentrations in azotemic solvent-treated
animals.
To further analyze serum 1,25(OH)2D3 concentrations in
animals on the above protocol, measurements were carried out
at the times shown in Figure 3. Time points were chosen after
preliminary experiments had indicated that the 1 ,25(OH)2D3
peak concentration occurred approximately eight hours after
intraperitoneal injection.
A
250
200
150
100
50
0
B
Intact Nx Nx Nx
bolus infusion
1 2 3 4
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Intact Nx Nx Nx
bolus infusion
Fig. 2. Effect of bolus versus continuous 1,25(OH)2D3 administration
on parathyroid gland weight (means SE); N = 13 to 19 glands per
group. Abbreviations are: intact, sham-operated control animals; Nx,
Nx-solvent. Symbols are: (*) p < 0.01 vs. Nx-solvent; (0) P < 0.05 vs.
Nx-solvent.
After intraperitoneal injection, 1 ,25(OH)2D3 concentrations
rose rapidly and reached a peak concentration of 170 to 200
pg/mi after eight hours (Fig. 3). This was approximately three-
to fourfold above the baseline concentration (58 11 pg/mI).
Thereafter, 1 ,25(OH)2D3 levels decreased to baseline within 48
hours after injection. The 1 ,25(OH)2D3 concentration time-
profile after a second injection (72 hr after the first injection)
was similar to that after the first injection. During infusion
treatment by osmotic minipumps, 1 ,25(OH)2D3 levels rose
approximately twofold during the first 48 hours (to 129 16
pg/mi) and subsequently remained stable until the end of the
experiment.
The calculated time-averaged increase over baseline in
1,25(OH)2D3 concentrations during six days (equivalent to the
area under the curve, AUC) was 254 pg/mI (42.3 pg/mL/24 hr) in
infusion-treated animals and 156 pg/mI (26.0 pg/m1124 hr) in
bolus-treated animals.
Discussion
The aim of this study was to investigate whether the temporal
pattern of 1 ,25(OH)2D3 administration (that is, intermittent
bolus administration or continuous administration) differen-
tially affected parathyroid function in experimental renal hyper-
parathyroidism. Pre-pro-PTH mRNA concentrations and PTH
serum concentrations were used as indicators of parathyroid
function. Our data showed that 1 ,25(OH)2D3 given as a bolus
injection was more effective in suppressing hyperparathyroid-
ism than the same total dose of 1 ,25(OH)2D3 given as a
continuous infusion by osmotic minipump. Parathyroid prolif-
eration as assessed by measuring parathyroid gland weight, and
in one study DNA synthesis, were also less pronounced after
bolus administration of I ,25(OH)2D3 than after continuous
infusion.
In agreement with others [27, 28], we found both an increase
in pre-pro-PTH/3-actin mRNA ratio and an increase in parathy-
roid weight in experimental uremia. It is justified to assume that
increased parathyroid weight reflected increased parathyroid
gland cell number, since previous stereological studies had
shown unchanged parathyroid cell volume in rats several days
after subtotal nephrectomy [26]. Similar to our results, Shvil et
al [28] had noted an approximately threefold elevation of
pre-pro-PTH mRNA concentrations in uremic rats. Other in-
vestigators [27, 29] had found a more marked degree of hyper-
parathyroidism in their models of uremic rats. The reason for
this is not immediately apparent, although differences in strain,
age and gender of animals might have played a role. It remains
to be shown if our data in animals with a more moderate degree
of hyperparathyroidism can also be extended to more severe
hyperparathyrodism.
Bolus administration of 1 ,25(OH)2D3 reduced pre-pro-PTH
mRNA to a level close to that in sham-operated control
animals. This finding was in agreement with previous studies
[27, 28] in which administration of 1 ,25(OH)2D3 also reduced
the pre-pro-PTH//3-actin mRNA ratios in parathyroid tissue of
uremic animals to control values. Although an effect of
I ,25(OH)2D3 on stability of pre-pro-PTH mRNA, at least in
part, cannot be excluded, l,25(OH)2D3 presumably acts by
decreasing the transcription of the pre-pro-PTH gene [30, 31].
This has, however, not been formally shown in uremia.
a)
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0
250
200
E
150
C.,
100
50
0
24 48 72 96 120 144
Time, hours
Fig. 3. Mean 1,25(OH)2D3 serum concentrations at various times after
(*) bolus injection of 35 pmol 1,25(OH)2D3 and at various times during(•) continuous infusion of 70 pmol 1,25(OH)2D3. N = 9 animals for
baseline concentration (0 hr), and N = 5 animals for each other time
point. SE was within 8% of means.
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When the two different modes of administration are com-
pared, it is crucial to verify that the total quantity of 1 ,25(OH)2D3
delivered is identical. The lesser efficacy of continuous infusion
was not explained by less delivery of I ,25(OH)2D3, as docu-
mented by measuring the time-averaged l,25(OH)2D3 serum
concentrations (AUC). Furthermore, correct delivery of
1 ,25(OH)2D3 by osmotic minipumps was monitored by testing
the function of minipumps. We considered several confounding
variables like growth of animals (final weight), food intake, and
vitamin D status. These factors did not explain the different
results between the two treatment modalities. We cannot ex-
clude, but consider unlikely, other confounding aspects of
intraperitoneal bolus injection of I ,25(OH)2D3 versus subcuta-
neous administration by osmotic minipump.
Both modes of 1 ,25(OH)2D3 administration led to a modest
increase in serum calcium and serum phosphate concentrations.
The increases were similar and do not explain the different
effects of the two modes of administration. This conclusion was
strengthened by previous findings that hypercalcemia does not
affect pre-pro-PTH mRNA in uremia [28], although this was not
explicitly demonstrated in our model. Even if hypercalcemia
had had an effect on PTH synthesis in uremia this would not
have invalidated the conclusions of this study.
The contrasting effects on parathyroid function of intermit-
tent versus continuous administration of I ,25(OH)2D3 were
presumably the result of different pharmacokinetics of the
hormone. Paradoxically, bolus administration of 1 ,25(OH)2D3
suppressed parathyroid function more effectively, although the
time-averaged mean increase over baseline in 1 ,25(OH)2D3
concentrations was only 60% of the mean increase after con-
tinuous administration. The peak 1 ,25(OH)2D3 concentrations
were, however, considerably higher after bolus administration
than during continuous infusion. Thus, the 1 ,25(OH)2D3 peak
concentration and not the time-averaged mean increase in
l,25(OH)2D3 serum concentration correlated best with the
changes in parathyroid function. One must concede that free
1 ,25(OH)2D3 concentrations were not measured so that differ-
ent binding of 1 ,25(OH)2D3 to the vitamin D binding protein
between groups (although unlikely) cannot be formally ruled
out.
The need for high peak serum levels of 1 ,25(OH)2D3 to
suppress PTH synthesis in uremia to a similar degree than in
normal conditions could be causally related to resistance to
l,25(OH)2D3 in uremia. It is unclear at which level of
1 ,25(OH)2D3 action resistance to the hormone occurs. Some
studies reported decreased vitamin D receptors in uremia [32,
33], thus suggesting a receptor defect. Another more recent
study [34], which failed to confirm diminished vitamin D
receptors in uremia, would, however, suggest a post-receptor
defect. Our study did not address this issue.
The main finding of this study, that is, the different efficacy of
intermittent versus continuous administration of 1 ,25(OH)2D3,
may have obvious implications for the treatment of secondary
hyperparathyroidism in uremic patients. Intermittent bolus
therapy under clinical conditions (intravenous or oral) achieves
higher 1 ,25(OH)2D3 serum peak concentrations [11] than daily
administration of low doses of 1 ,25(OH)2D3. The profile of
1 ,25(OH)2D3 serum concentrations after intrapentoneal admin-
istration was remarkably similar to profiles obtained after oral
ingestion of 1,25(OH)2D3 in normal men [35, 36]. In those
studies, peak concentrations were reached four to eight hours
after ingestion of 1 ,25(OH)2D3. Within 24 hours after adminis-
tration the I ,25(OH)2D3 concentrations had returned to base-
line.
We still lack some pieces of information required to give a full
interpretation of the above results. First, the dose-response
curve relating 1 ,25(OH)2D3 serum concentrations to pre-pro-
PTH mRNA levels has not been defined. Second, it has not
been thoroughly investigated whether intraglandular effects
triggered by 1 ,25(OH)2D3 persist beyond the time when the
hormone is present in the circulation. Data from experiments in
vitro [37] have shown that reduction of pre-pro-PTH mRNA by
1 ,25(OH)2D3 in cultured parathyroid cells was maintained for at
least four days. Our own preliminary data [38] have shown that the
reduction of pre-pro-PTH mRNA in normal rats was maintained
for up to six days after a single dose of 200 pmol 1 ,25(OH)2D3.
Clinical observations on the time course of intact PTH plasma
concentrations after a single oral dose of 2 g 1 ,25(OH)2D3 also
point to prolonged effects of a bolus of 1 ,25(OH)2D3 [39]. The
possibility of prolonged effects of I ,25(OH)2D3 on parathyroid
glands in vivo is further supported by a report [40] that once-
weekly administration of 1 ,2S(OH)2D3 to patients on mainte-
nance hemodialysis significantly reduced PTH(l—84) concentra-
tions within four weeks. An explanation for the higher efficacy
of bolus administration could be provided by (i) a flat dose-
response curve for suppression of pre-pro-PTH mRNA concen-
trations in response to 1 ,25(OH)2D3 serum concentrations, and
(ii) by persistence of 1 ,25(OH)2D3-induced suppression of pre-
pro-PTH mRNA in the parathyroid glands. A further possibility
would be differential regulation of vitamin D receptor expres-
sion in parathyroid glands, but this issue was not addressed in
the present study.
We deliberately administered a low dose of 1 ,25(OH)2D3 in
order to obtain information which can be extrapolated to
therapeutically relevant doses in humans. Based on our results
it is justified to conduct a clinical trial to investigate whether the
same total dose of 1 ,25(OH)2D3 affects PTH(l—84) concentra-
tions differently when given at different intervals, that is, daily
smaller doses versus administration of higher bolus doses at
longer intervals.
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